BOSTON & GENEVA--(BUSINESS WIRE)--Join Dr. Susan M. Dallabrida, Senior Scientific Advisor, PHT Consulting Services, for a webinar, “Integrating ePRO with Glucometers: Electronic Capture of Blood Glucose Readings in Multinational Diabetes Populations,” April 23, at 10:00-11:00am EDT and 2:00-3:00pm EDT. PHT is the leading provider of innovative technology systems used to collect patient-driven eData for clinical research.
Patient-reported outcome (PRO) and electronic PRO (ePRO) measures are standard tools for directly eliciting the patient experience for Clinical Outcome Assessments (COAs). The 2009 FDA Guidance for Industry Patient Reported Outcome Measures: Use in Medical Product Development to Support Label Claims highlights the importance of PROs and other Clinical Outcome Assessment (COAs) in clinical research. Increasingly, diabetes therapies have been leveraging COAs and electronic COAs to demonstrate treatment benefit for patients.
This one-hour webinar is designed for professionals in protocol development, health outcomes, medical affairs, diabetes, regulatory affairs, clinical operations, and data management. It will review findings from multiple global diabetes programs, and reveal how capture of blood glucose levels by finger stick monitoring integrated with a handheld electronic device:
- Obviates hypoglycemia underreporting and inaccuracies
- Generates blood glucose frequency data that conforms to a more Gaussian distribution of continuous glucose monitoring (CGM) than paper data
- Shows an incidence rate of hypoglycemia that is in line with CGM
At the conclusion of the webinar, participants will understand:
- Key benefits of electronic collection of blood glucose measures
- Parallels between electronic self-monitoring and continuous monitoring of blood glucose
- Improved data completeness and quality with electronic capture versus paper
Dr. Susan Dallabrida has more than 20 years of experience in clinical trial design, strategy, and R&D in a broad range of therapeutic areas. She has led multiple cross-functional drug discovery and product development teams and collaborations. Dr. Dallabrida has 20 peer-reviewed articles, 14 grants, 3 patents, 15 abstracts and 29 conference presentations. Her 17 awards include the Harvard Catalyst Pilot Award and David Bray Scholars in Medicine from Harvard Medical School, Young Investigator’s Awards, NIH grants, biotechnology/pharmaceutical sponsored funding (Genentech, Amgen, AstraZeneca), and foundational grants (American Heart Association, Heart and Stroke Foundation, Plastic Surgery Education Foundation, Leet/Guthrie Patterson Trust Foundation). Dr. Dallabrida received a B.A. in Chemistry and a B.S. in Biology, both cum laude, from Bloomsburg University and a Ph.D. in Biochemistry and Molecular Biology from Pennsylvania State University.
Register at: http://goo.gl/4RXsZ
About PHT Corporation
PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial programs with greater confidence, ease and accuracy. Proven PHT eCOA (electronic Clinical Outcome Assessment) Systems collect patient-driven eData via smartphones, tablets and the web. This data, available via the PHT StudyWorksTM online portal, provides sponsors and clinicians with a real time window into how patients feel and function. PHT has helped trial sponsors collect patient-driven eData in 600+ global trials resulting in 16 regulatory approvals. PHT offers the regulatory, technological, and scientific expertise today’s market demands and patients deserve. Visit www.phtcorp.com for more information on PHT. Follow PHT on LinkedIn, Twitter and YouTube.